Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07592273 · ClinicalTrials.gov registry record · Phase 2
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
A Phase 2 study, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 576
- Enrollment target
NCT07592273: Recruiting Phase 2 study, sponsored by AbbVie.
NCT07592273 is a Phase 2 study that is actively recruiting participants, run by AbbVie. The registered enrollment target is 576 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (333% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07592273, a Phase 2 study, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 576 participants
- Enrollment target
Study Summary
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy administered in the suprachoroidal space (SCS) for the treatment of diabetic retinopathy (DR) and prevention of vision-threatening events (VTEs) in participants with non-proliferative DR (NPDR) without center-involved diabetic macular edema (CI-DME). This study will consist of 3 portions: a Phase 2b portion, a Phase 3 portion, and a bilateral treatment portion. Approximately 576 adult participants will be enrolled in the study across multiple sites in the United States and Puerto Rico. In the Phase 2b and Phase 3 portions, participants will be randomized to different groups to receive sura-vec and prophylactic steroids or sham and artificial tears in their study eye. If assigned to sham, participants will be given an opportunity to cross over and receive treatment with sura-vec. In the bilateral treatment portion, participants will be enrolled to receive sura-vec and prophylactic steroids in both eyes. In all 3 portions, follow-up in the study will continue through 5 years following administration of sura-vec in each eye. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Primary Outcome
The DRSS is a scale the measures the severity of DR with a higher score indicating greater severity.
Interventions
- DRUG Sham
- DRUG Topical Steroid
- DRUG Artificial Tears
- DRUG Surabgene Lomparvovec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2036-01 |
| Phase | Phase 2 |
What NCT07592273 shows while recruiting
NCT07592273 is an interventional study that assigns participants to a tested intervention. The registered 576 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (333% higher).
The record links to 0 conditions, and to 4 interventions - of which Sham is the first listed.
NCT07592273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07592273 about?
NCT07592273 is a clinical study titled "Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema". Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lompa...
What is the current status of trial NCT07592273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 576 participants. The study started on 2026-06-01. Estimated completion is 2036-01.
What interventions are being tested in trial NCT07592273?
The interventions under investigation include: Sham (DRUG), Topical Steroid (DRUG), Artificial Tears (DRUG), Surabgene Lomparvovec (DRUG).
Who is sponsoring clinical trial NCT07592273?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07592273's enrollment target sits among peer trials
576 59th of 2000 higher than 1,942 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI